Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Details:
FLT180a (verbrinacogene setparvovec), uses a potent AAVS3 capsid rationally designed for effective targeting and transduction of liver cells and containing an expression cassette encoding a gain of function Padua variant of human factor IX (FIX).
Lead Product(s): Verbrinacogene Setparvovec
Therapeutic Area: Genetic Disease Product Name: FLT180a
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: University College London
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2022
Details:
B-LIEVE is a Phase 1/2 dose confirmation trial of FLT180a (verbrinacogene setparvovec) using a short course of prophylactic immune management with the goal of normalizing FIX levels in patients with severe and moderately severe hemophilia B.
Lead Product(s): Verbrinacogene Setparvovec
Therapeutic Area: Genetic Disease Product Name: FLT180a
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
Details:
FLT180a (verbrinacogene setparvovec) candidate uses a potent, rationally designed AAVS3 capsid containing an expression cassette encoding a gain of function Padua variant of human Factor IX (FIX).
Lead Product(s): Verbrinacogene Setparvovec
Therapeutic Area: Genetic Disease Product Name: FLT180a
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2022
Details:
FLT180a (verbrinacogene setparvovec) is a next-generation AAV gene therapy for people with haemophilia B, to treat and potentially cure debilitating genetic disorders, also improved assessment of host-cell derived DNA impurities encapsidated during AAV manufacturing.
Lead Product(s): Verbrinacogene Setparvovec
Therapeutic Area: Genetic Disease Product Name: FLT180a
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
FLT190, an investigational AAV gene therapy in development for treatment of patient with Fabry disease. Is consist of a potent, rationally designed capsid containing an expression cassette with a codon-optimized human α-Gal A cDNA under control of a liver-specific promoter.
Lead Product(s): FLT190
Therapeutic Area: Genetic Disease Product Name: FLT190
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2022
Details:
The proceeds will support the advancement of Freeline’s clinical-stage programs and the extension of the Company’s scientific capabilities and platform technologies to additional disease areas.
Lead Product(s): Verbrinacogene Setparvovec
Therapeutic Area: Genetic Disease Product Name: FLT180a
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Syncona Portfolio Limited
Deal Size: $26.1 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 15, 2022
Details:
Freeline intends to use the net proceeds from this offering to fund activities relating to the continued development of its product candidates, FLT180a and gene therapy platform and for other general corporate purposes.
Lead Product(s): Verbrinacogene Setparvovec
Therapeutic Area: Genetic Disease Product Name: FLT180a
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Syncona Portfolio Limited
Deal Size: $26.1 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 10, 2022
Details:
B-LIEVE, a trial of FLT180a, proprietary AAVS3, deliver functioning gene of variant of human FIX, manufactured at commercial scale and starting dose of 7.7e11 vg/kg and a short course of prophylactic immune management with goal of normalizing FIX levels.
Lead Product(s): Verbrinacogene Setparvovec
Therapeutic Area: Genetic Disease Product Name: FLT180a
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
The presentations will include updated data from ongoing Phase 1/2 MARVEL-1 clinical trial evaluating FLT190 for the treatment of patients with Fabry disease and the clinical trial design for GALILEO-1, a Phase 1/2 study of FLT201 in adult patients with Gaucher disease Type 1.
Lead Product(s): FLT190
Therapeutic Area: Genetic Disease Product Name: FLT190
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2022
Details:
The Company reported an interim program update on Patients in its Phase 1/2 MARVEL-1 dose-finding trial of FLT190. FLT190 appears to be having a significant impact on α-Gal A activity and disease process in Fabry, which is the underlying goal and promise of the FLT190 program.
Lead Product(s): FLT190
Therapeutic Area: Genetic Disease Product Name: FLT190
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2021
